IL-6 secreted from Cancer-Associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling

Journal of Thoracic Oncology

Volumn 11, Issue 9, 2016, Pages 1482-1492

  Shintani, Yasushi ^a   Fujiwara, Ayako ^a   Kimura, Toru ^a   Kawamura, Tomohiro ^a   Funaki, Soichiro ^a   Minami, Masato ^a   Okumura, Meinoshin ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Epithelialmesenchymal transition; Fibroblast; IL 6; NSCLC; TGF B

Indexed keywords

CISPLATIN; INTERLEUKIN 6; NERVE CELL ADHESION MOLECULE; SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; IL6 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMA CELL; CELL ACTIVATION; CELL INTERACTION; CONDITIONED MEDIUM; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CARCINOMA, NON-SMALL-CELL LUNG; CELL COMMUNICATION; LUNG NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CANCER-ASSOCIATED FIBROBLASTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL COMMUNICATION; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84987788582     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.05.025     Document Type: Article

References (37)

1. Bremnes RM, Veve R, Gabrielson E, et al. Highthroughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol. 2002;20:2417-2428.
2. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274-284.
3. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15:740-746.
4. Scheel C, Weinberg RA. Cancer stem cells and epithelialmesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012;22:396-403.
5. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559-1564.
6. Zhuo WL, Wang Y, Zhuo XL, et al. Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res Commun. 2008;369:1098-1102.
7. Zhuo W, Wang Y, Zhuo X, et al. Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway. Lung Cancer. 2008;62:8-14.
8. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of nonsmall- cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005;65:9455-9462.
9. Shintani Y, Okimura A, Sato K, et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg. 2011;92:1794-1804 [discussion 1804].
10. Abulaiti A, Shintani Y, Funaki S, et al. Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF-beta signaling by IL-6. Lung Cancer. 2013;82:204-213.
11. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest. 2007;117:3660-3663.
12. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263-266.
13. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-899.
14. Yan HQ, Huang XB, Ke SZ, et al. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxiatelangiectasia mutated/NF-kappaB pathway activation. Cancer Sci. 2014;105:1220-1227.
15. Chang CH, Hsiao CF, Yeh YM, et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer. 2013;132:1977-1985.
16. Yamada D, Kobayashi S, Wada H, et al. Role of crosstalk between interleukin-6 and transforming growth factorbeta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer. 2013;49:1725-1740.
17. Yao Z, Fenoglio S, Gao DC, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A. 2010;107:15535-15540.
18. Endo H, Okami J, Okuyama H, et al. Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation. J Thorac Oncol. 2013;8:131-139.
19. Shintani Y, Maeda M, Chaika N, et al. Collagen I promotes epithelial-To-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am J Respir Cell Mol Biol. 2008;38:95-104.
20. McCarty KS Jr, Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46:4244s-4248s.
21. Matsubara D, Morikawa T, Goto A, et al. Subepithelial myofibroblast in lung adenocarcinoma: A histological indicator of excellent prognosis. Mod Pathol. 2009;22:776-785.
22. Liu X. Inflammatory cytokines augments TGF-beta1- induced epithelial-mesenchymal transition in A549 cells by up-regulating TbetaR-I. Cell Motil Cytoskeleton. 2008;65:935-944.
23. Poth KJ, Guminski AD, Thomas GP, et al. Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma. Mol Cancer Ther. 2010;9:2430-2439.
24. Kim HJ, Oh GS, Lee JH, et al. Cisplatin ototoxicity involves cytokines and STAT6 signaling network. Cell Res. 2011;21:944-956.
25. Duan S, Tsai Y, Keng P, et al. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-Apoptotic and DNA repair associated molecules. Oncotarget. 2015;6:27651-27660.
26. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41: 2502-2512.
27. Ge Q, Moir LM, Black JL, et al. TGFbeta1 induces IL-6 and inhibits IL-8 release in human bronchial epithelial cells: The role of Smad2/3. J Cell Physiol. 2010;225: 846-854.
28. Goulet S, Bihl MP, Gambazzi F, et al. Opposite effect of corticosteroids and long-Acting beta(2)-Agonists on serum-And TGF-beta(1)-induced extracellular matrix deposition by primary human lung fibroblasts. J Cell Physiol. 2007;210:167-176.
29. Tuxhorn JA, Ayala GE, Smith MJ, et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002;8:2912-2923.
30. Doldi V, Callari M, Giannoni E, et al. Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. Oncotarget. 2015;6:31441-31460.
31. Aoki H, Ohnishi H, Hama K, et al. Existence of autocrine loop between interleukin-6 and transforming growth factor-beta1 in activated rat pancreatic stellate cells. J Cell Biochem. 2006;99:221-228.
32. Luckett-Chastain LR, Gallucci RM. Interleukin (IL)-6 modulates transforming growth factor-beta expression in skin and dermal fibroblasts from IL-6-deficient mice. Br J Dermatol. 2009;161:237-248.
33. Shintani Y, Abulaiti A, Kimura T, et al. Pulmonary fibroblasts induce epithelial mesenchymal transition and some characteristics of stem cells in non-small cell lung cancer. Ann Thorac Surg. 2013;96:425-433.
34. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle. 2006;5:1597-1601.
35. Vicent S, Sayles LC, Vaka D, et al. Cross-species functional analysis of cancer-Associated fibroblasts identifies a critical role for CLCF1 and IL-6 in nonsmall cell lung cancer in vivo. Cancer Res. 2012;72: 5744-5756.
36. Osuala KO, Sameni M, Shah S, et al. Il-6 signaling between ductal carcinoma in situ cells and carcinomaassociated fibroblasts mediates tumor cell growth and migration. BMC Cancer. 2015;15:584.
37. Lee SO, Yang X, Duan S, et al. IL-6 promotes growth and epithelial-mesenchymal transition of CD133 cells of non-small cell lung cancer. Oncotarget. 2016;7:6626- 6638.